Close Menu

Editor's Pick

The California health system has expanded its partnership with CancerIQ to integrate risk assessment and oncology patient management into its EHR.

The randomized data continue to distinguish Genomic Health's test for node-negative women, while new questions come to the fore node-positive disease and other areas of clinical care.

The protocol involves using CRISPR-Cas9 gene editing to knock out the NRF2 gene in KRAS-positive NSCLC patients who have become resistant to chemotherapy.

Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.  

The approval of two molecularly targeted, tissue-agnostic therapies, has shown researchers that there is a path forward for other pan-cancer markers.

The firm launched a study this year to validate the new CRC-specific immune-transcriptomic assay, aiming to obtain regulatory approval in Europe.

The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.

The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.

The firm's "TuMatch" assay integrates patient whole-exome sequencing data and fruit fly models to develop a personalized drug therapy service for cancer patients.

The year-old Princess Máxima Center, based in Utrecht, has turned to bioinformatics firm The Hyve to address integration and interoperability issues.

Pages